NEW YORK – Population health management services company Lightbeam Health Solutions said on Monday that it has partnered with Ambry Genetics to provide genetic testing data to help organizations predict patients' increased risk for common cancers and chronic conditions.
The collaboration is expected to produce tools for early detection and prevention that will allow clinicians to quickly identify, assess, and engage patients who meet specific risk factors, the companies said. The CARE (Comprehensive, Assessment, Risk, and Education) Program will be integrated into the Lightbeam Platform.
Financial and other terms of the deal were not disclosed.
"We believe this partnership with Ambry Genetics will positively impact lives with its ability to indicate whether a person is high-risk for cancer or other diseases," Lightbeam CEO Pat Cline said in a statement. "In combination with our industry-leading analytics platform, Ambry's genetic data further enhances how Lightbeam clients can improve quality, reduce costs, and positively impact outcomes for the populations they serve."
Rob Guigley, Ambry's chief commercial officer, further noted that the partnership will expand the ability of patients and providers to make informed preventive healthcare decisions.